AACR Journals | Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity. Kim SI, Park AK, Chaurasiya S, Kang S, Lu J, Yang A, Sivanandam V, Zhang Z, Woo Y, Priceman SJ, Fong Y, Warner SG.Mol Cancer Ther. 2021 Jan;20(1):173-182. doi: 10.1158/1535-7163.MCT-20-0405. Epub 2020 Dec 1.PMID: 33262221

Science Translational Medicine | Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Park AK, Fong Y, Kim SI, Yang J, Murad JP, Lu J, Jeang B, Chang WC, Chen NG, Thomas SH, Forman SJ, Priceman SJ. Sci Transl Med. 2020 Sep 2;12(559):eaaz1863. doi: 10.1126/scitranslmed.aaz1863.PMID: 32878978

Cancer Treatment Research | CAR T Cell Therapy Progress and Challenges for Solid Tumors. Stern LA, Jonsson VD, Priceman SJ. Cancer Treat Res. 2020;180:297-326. doi: 10.1007/978-3-030-38862-1_11.PMID: 32215875

Current Opinion in Oncology | Smart CARs engineered for cancer immunotherapy. Priceman SJ, Forman SJ, Brown CE.Curr Opin Oncol. 2015 Nov;27(6):466-74. doi: 10.1097/CCO.0000000000000232.PMID: 26352543 Free PMC article. Review.

Therapeutic Advances in Medical Oncology | CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study Yuan Yuan, Colt Egelston, Oscar Colunga Flores, Shyambabu Chaurasiya, David Lin, Helen Chang, Leslie Mi Ok Chong, Amanda Seiz, Monil Shah, W. Hans Meisen, Aileen Tang, Norma Martinez, Wichanee Pickett, Mireya Murga, Susan E. Yost, Daphne Stewart, Jianying Zhang, Nicholas Ede, Badri Modi, Jonathan Kessler, Jamie Rand, and Yuman Fong

International Journal of Molecular Science | Anti-Tumor Immunogenicity of the Oncolytic Virus CF33-hNIS-antiPDL1 against Ex Vivo Peritoneal Cells from Gastric Cancer Patients. Zhang, Z.; Yang, A.; Chaurasiya, S.; Park, A.K.; Kim, S.-I.; Lu, J.; Valencia, H.; Fong, Y.; Woo, Y. Int. J. Mol. Sci. 2023, 24, 14189. https://doi.org/10.3390/ijms241814189

Molecular Cancer Therapeutics | Shyambabu Chaurasiya, Hannah Valencia, Zhifang Zhang, Sang-In Kim, Annie Yang, Jianming Lu, Yanghee Woo, Susanne G. Warner, Nicholas J. Ede, Yuman Fong; An Oncolytic Poxvirus Encoding hNIS, Shows Antitumor Efficacy and Allows Tumor Imaging in a Liver Cancer Model. Mol Cancer Ther 2023

Journal for ImmunoTherapy of Cancer | Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases

Molecular Therapy Oncolytics | PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1

Molecular Therapy Oncolytics | Priming stroma with a vitamin D analog to optimize viroimmunotherapy for pancreatic cancer

Molecular Therapy | Methods & Clinical Development / Chaurasiya etal. | A Comprehensive Preclinical Study in Support of Clinical Trial using the Oncolytic Chimeric Poxvirus CF33-hNIS-anti-PD-L1 for the Treatment of Breast Cancer

Cancer Gene Therapy | Chaurasiya, S., Fong, Y. Viroimmunotherapy for breast cancer: promises, problems and future directions.

AACR Journals | Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity

Science Translational Medicine | Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | Vitamin D as a Primer for Oncolytic Viral Therapy in Colon Cancer Models

MDPI Cancers Journal | Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges 26 June 2020 This article belongs to the Special Issue Oncolytic Virus Therapy Against Cancer

NATURE | Cancer Gene Therapy volume 27, pages 125–135 (2020) | A chimeric poxvirus with J2R (thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models

ONCOIMMUNOLOGY 2020, VOL. 9, NO. 1, e1729300 (12 pages) | Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model

Mol Ther Oncolytics. 2019, 11;13:82-92 | A Novel Chimeric Poxvirus Encoding hNIS Is Tumor-Tropic, Imageable, and Synergistic with Radioiodine to Sustain Colon Cancer Regression

Mol Ther Oncolytics 2018 June 29; 9 | Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds

Mol Ther Oncolytics 2018 June 29; 9 | A Novel Oncolytic Chimeric OrthopoxvirusEncoding Luciferase Enables Real-Time View of Colorectal Cancer Cell Infection

Mol Ther Oncolytics 2018 June 29; 9 | Endogenous AKT Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirusin Triple-Negative Breast Cancer

J Transl Med. 2018 Apr 26; 16:110 | Novel Oncolytic Chimeric OrthopoxvirusCauses Regression of Pancreatic Cancer Xenografts and Exhibits Abscopal Effect at a Single Low Dose

Surgery 2018 February; 163(2) | Novel Chimeric Parapoxvirus CF189 as an Oncolytic Immunotherapy in Triple-Negative Breast Cancer

Cancer vaccines hold potential in the immuno-oncology space as an alternative to monoclonal antibodies or other approaches – but why have they not yet gained more traction in the immuno-oncology space? Professor and director of vaccine research at The Ohio State University, Pravin Kaumaya, once described B cell epitope cancer vaccines as a “new paradigm for combination immunotherapies”.

Roisin McGuigan, Editor, Immuno-Oncology Insights, speaks to Pravin TP Kaumaya, Professor and Director of Vaccine Research at The Ohio State University

Guo, L., Kaumaya, P.T.P. First prototype checkpoint inhibitor B-cell epitope vaccine (PD1-Vaxx) en route to human Phase 1 clinical trial in Australia and USA: exploiting future novel synergistic vaccine combinations. British Journal of Cancer (2021).

Pravin T. P. Kaumaya , Linlin Guo , Jay Overholser , Manuel L. Penichet & Tanios Bekaii-Saab, Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model, ONCOIMMUNOLOGY 2020, VOL. 9, NO. 1, e1818437.

PT Kaumaya, B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine, Future Oncol. 2020 Aug;16(23):1767-1791

Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion | Tobias, J. etal

Annals of Oncology, VOLUME 34, SUPPLEMENT 1, S4, JUNE 2023 | Tobias, J etal, PD-8 HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus SOC chemotherapy in patients with HER2+ advanced stomach cancer – correlation of the antibody responses and clinical outcome

Ede NJ, Good AJ, Tobias J, GarnerSpitzer E, Zielinski CC and Wiedermann U (2022) Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers. Front. Oncol. 12:939356. doi: 10.3389/fonc.2022.939356

Joshua Tobias, Ursula Wiedermann etal Cancers 2022, 14(22), 5678; [ https://doi.org/10.3390/cancers14225678 ], Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer

Joshua Tobias, Ursula Wiedermann etal Translational Oncology. Volume 19, May 2022, 101378 | Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model

J. Tobias, E. Garner-Spitzer, M. Drini & U. Wiedermann ESMO OPEN Cancer Horizons | Vaccination against Her-2/neu, with focus on peptide-based vaccines

J. Tobias, P. Steinberger, M. Drinic & U. Wiedermann ESMO OPEN Cancer Horizons | Emerging targets for anticancer vaccination: PD-1

Ursula Wiedermann, Erika Garner-Spitzer, Yee Chao, Marina Maglakelidze, Iurie Bulat, Arunee Dechaphunkul, Wichit Arpornwirat, Chaiyut Charoentum, Chia-Jui Yen, Thomas Yau, Suebpong - Tanasanvimon, Jedzada Maneechavakajorn, Aumkhae Sookprasert, Li-Yuan Bai, Wen-Chi Chou, Teerapat Ungtrakul, Mirjana Drinić, Joshua Tobias, Christoph C Zielinski, Leslie Chong, Nicholas J Ede, Mark T Marino and Anthony J Good. Clinical and immunologic responses to a B-cell epitope vaccine in HER2/neu overexpressing advanced gastric cancer patients - results from Phase 1b trial IMU.ACS.001.

Clin Cancer Res April 28 2021 DOI: 10.1158/1078-0432.CCR-20-3742

Joshua Tobias, Claire Battin, Annika De Sousa Linhares, Michael Lebens, Karin Baier, Katharina Ambroz, Mirjana Drinic ́ , Sandra Högler, Aleksandra Inic-Kanada, Erika Garner-Spitzer, Matthias Preusser, Lukas Kenner, Michael Kundi, Christoph C. Zielinski, Peter Steinberger and Ursula Wiedermann , A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors, Front. Immunol., 27 May 2020

Tobias J, Jasinska J, Baier K, Kundi M, Ede N, Zielinski C, Wiedermann U. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide. BMC Cancer. 2017 Feb 9;17(1):118. doi: 10.1186/s12885-017-3098-7

Wiedermann U and C.C. Zielinski. Vaccination for prevention and treatment of breast cancer. Breast Cancer Res Treat. 2013 Feb;138(1):1-12

Wiedermann U, C. Wiltschke, J. Jasinska, M. Kundi, R. Zurbriggen, E. Garner-Spitzer. R. Bartsch, G. Steger, H. Pehamberger, O. Scheiner, C.C. Zielinski. 2010. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treat. 119 (3):673-83.

Wagner S, C. Krepler, D. Allwardt, J. Latzka, S. Strommer, O. Scheiner, H. Pehamberger, U. Wiedermann, C. Hafner, and H. Breiteneder. 2008. Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine. Clin Cancer Res.;14(24):8178-83.

Wagner, S.; J. Jasinska, H. Breiteneder, M. Kundi, H. Pehamberger, O. Scheiner, C. C. Zielinski, and U. Wiedermann. 2007. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat. 2007 Jan 3; 106(1):29-38.

Brämswig KH, Knittelfelder R, Gruber S, Untersmayr E, Riemer AB, Szalai K, Horvat R, Kammerer R, Zimmermann W, Zielinski CC, Scheiner O, Jensen-Jarolim E. Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice. Clin Cancer Res. 2007 Nov 1;13(21):6501-8.

Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, Scheiner O, Jensen-Jarolim E. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res. 2007 Apr 1;67(7):3406-11.

Hafner, C.; H. Breiteneder, S. Ferrone, C. Thallinger, S. Wagner, W. M. Schmidt, J. Jasinska, M. Kundi, K. Wolff, C. C. Zielinski, O. Scheiner, U. Wiedermann*, and H. Pehamberger. 2005. Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer, 114:426.

Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst. 2005 Nov 16;97(22):1663-70.

Jasinska J, WagnerS, RadauerC, SedivyR, BrodowiczT, WiltschkeC, Breiteneder H, Pehamberger H, Scheiner O, WiedermannU*, Zielinski CC. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int. J. Cancer. 2003. 20; 107:976-83.